Apollomics (APLM) Other Non-Current Liabilities (2023 - 2025)
Apollomics (APLM) posted quarterly Other Non-Current Liabilities of $3.0 million for Q4 2025, up 139.81% quarter-over-quarter from $1.3 million in Q2 2023.
Apollomics (APLM) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Apollomics (APLM) has reported Other Non-Current Liabilities for 2 consecutive years, with $3.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2025 stood at $3.0 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, up 2841.18% from the prior year.
- Other Non-Current Liabilities advanced to $3.0 million in Q4 2025 per APLM's latest filing, from $1.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.0 million in Q4 2025 and bottomed at $1.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Apollomics | 35.18 Mn | 31.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.00 Mn |
| Jun 30, 2023 | 1.25 Mn |